Related references
Note: Only part of the references are listed.A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats
A. Bhatwadekar et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes
Kazuo Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2008)
RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis
Jiancheng Guo et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGES (RAGE) expression
Sho-ichi Yamagishi et al.
MICROVASCULAR RESEARCH (2008)
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species
Sho-Ichi Yamagishi et al.
OPHTHALMIC RESEARCH (2008)
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGES in both diabetic and non-diabetic subjects
K. Nakamura et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes
Sho-ichi Yamagishi et al.
CURRENT DRUG TARGETS (2007)
Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy
Yumiko Yoshida et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Pyridoxal phosphate prevents progression of diabetic nephropathy
Sakurako Nakamura et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties
A. Hoang et al.
DIABETOLOGIA (2007)
Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy
Masahiko Yokoi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease
Kazuo Nakamura et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Telmisartan, an angiotensin II type I receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chernoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ activation
T. Matsui et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2007)
Mechanisms of Disease: a 'DAMP' view of inflammatory arthritis
Dirk Foell et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2007)
Vitamin B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine and copper
Naoko Endo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
Per M. Humpert et al.
CARDIOVASCULAR DIABETOLOGY (2007)
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
Susan J. Zieman et al.
JOURNAL OF HYPERTENSION (2007)
Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1
Nadjat Ouslimani et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products
Yuichi Kaji et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes
Junnosuke Miura et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes
Sho-ichi Yamagishi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats
Sho-ichi Yamagishi et al.
OPHTHALMIC RESEARCH (2007)
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes
Kazuo Nakamura et al.
MOLECULAR MEDICINE (2007)
Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells
T. Matsui et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2007)
Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation
T. Yoshida et al.
DIABETOLOGIA (2006)
Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
K. C. B. Tan et al.
DIABETOLOGIA (2006)
Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan
Yoshifumi Saisho et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein
Giuseppina Basta et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
RAGE control of diabetic nephropathy in a mouse model -: Effects of RAGE gene disruption and administration of low-molecular weight heparin
Khin-Mar Myint et al.
DIABETES (2006)
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects
Sho-ichi Yamagishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Advanced glycation end products - Sparking the development of diabetic vascular injury
Alison Goldin et al.
CIRCULATION (2006)
Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy
Sarah X. Zhang et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2006)
Development of an ELISA for esRAGE and its application to type 1 diabetic patients
Shigeru Sakurai et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes
K. -C. Chang et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2006)
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression
Sho-ichi Yamagishi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis
Sho-Ichi Yamagishi et al.
MICROVASCULAR RESEARCH (2006)
Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties
Sho-ichi Yamagishi et al.
MICROVASCULAR RESEARCH (2006)
Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins
BE Brown et al.
DIABETOLOGIA (2006)
The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats: Preventive versus curative treatment
MF Usta et al.
JOURNAL OF SEXUAL MEDICINE (2006)
Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes
Katsuhiko Takenaka et al.
CURRENT NEUROVASCULAR RESEARCH (2006)
Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema
H Funatsu et al.
OPHTHALMOLOGY (2006)
Pleiotropic effects of nifedipine on atherosclerosis
Sho-Ichi Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy
S Yamagishi et al.
MEDICAL HYPOTHESES (2006)
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice
FY Chow et al.
KIDNEY INTERNATIONAL (2006)
Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice
C Demiot et al.
CARDIOVASCULAR RESEARCH (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis
H Koyama et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension
K Nakamura et al.
MICROVASCULAR RESEARCH (2005)
Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients - Its possible association with diabetic vascular complications
N Katakami et al.
DIABETES CARE (2005)
Interactions between renin angiotensin system and advanced glycation in the kidney
MC Thomas et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression
S Yamagishi et al.
FEBS LETTERS (2005)
Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage
PA Voziyan et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
The RAGE axis in early diabetic retinopathy
GR Barile et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy
JM Forbes et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy
M Yokoi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2005)
Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF
S Yamagishi et al.
CELL AND TISSUE RESEARCH (2005)
The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure
WC Little et al.
JOURNAL OF CARDIAC FAILURE (2005)
Diabetic vascular complications: Pathophysiology, biochemical basis and potential therapeutic strategy
S Yamagishi et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Telmisartan is a promising cardiometabotic sartan due to its unique PPAR-gamma-inducing property
S Yamagishi et al.
MEDICAL HYPOTHESES (2005)
Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes
M Challier et al.
CLINICAL CHEMISTRY (2005)
Pigment epithelium-derived factor inhibits TNF-α-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation
SI Yamagishi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2004)
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling
S Yamagishi et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice
QL Fan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis
JM Forbes et al.
DIABETES (2004)
Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants
JC Mamputu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy
WK Bolton et al.
AMERICAN JOURNAL OF NEPHROLOGY (2004)
NF-κB activation and overexpression of regulated genes in human diabetic nephropathy
S Mezzano et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2004)
Thiazolidinediones reduces endothelial expression of receptors for advanced glycation end products
N Marx et al.
DIABETES (2004)
Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes
S Okada et al.
DIABETES (2003)
The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques - Role of glycemic control
F Cipollone et al.
CIRCULATION (2003)
PEDF: A multifaceted neurotrophic factor
J Tombran-Tink et al.
NATURE REVIEWS NEUROSCIENCE (2003)
LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
JL Figarola et al.
DIABETOLOGIA (2003)
The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats
NL Alderson et al.
KIDNEY INTERNATIONAL (2003)
Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties
SI Yamagishi et al.
MICROVASCULAR RESEARCH (2003)
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes
R Candido et al.
CIRCULATION RESEARCH (2003)
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
TM Wendt et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Effects of ramipril in nondiabetic nephropathy:: improved parameters of oxidatives stress and potential modulation of advanced glycation end products
K Sebeková et al.
JOURNAL OF HUMAN HYPERTENSION (2003)
Central role of RAGE-dependent neointimal expansion in arterial restenosis
T Sakaguchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy
BO Boehm et al.
DIABETOLOGIA (2003)
Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation
Y Inagaki et al.
DIABETOLOGIA (2003)
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts
PJ Thornalley
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2003)
Novel inhibitors of advanced glycation endproducts
S Rahbar et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2003)
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice
LG Bucciarelli et al.
CIRCULATION (2002)
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy
JM Forbes et al.
DIABETES (2002)
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin
T Okamoto et al.
FASEB JOURNAL (2002)
Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products:: Biochemical mechanisms
T Miyata et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody
A Flyvbjerg et al.
DIABETES (2002)
Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro
T Okamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties
S Yamagishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy
Y Matsumoto et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2002)
Diabetes and advanced glycation endproducts
H Vlassara et al.
JOURNAL OF INTERNAL MEDICINE (2002)
A post-amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation
PA Voziyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Chelating activity of advanced glycation end-product inhibitors
DL Price et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Biochemistry and molecular cell biology of diabetic complications
M Brownlee
NATURE (2001)
Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease
J Spranger et al.
DIABETES (2001)
Improved arterial compliance by a novel advanced glycation end-product crosslink breaker
DA Kass et al.
CIRCULATION (2001)
Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells
K Shimoi et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Vascular endothelial growth factor enhances atherosclerotic plaque progression
FL Celletti et al.
NATURE MEDICINE (2001)
Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation
S Rahbar et al.
CLINICA CHIMICA ACTA (2000)
The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear Factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells
N Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions - Mechanism of action of pyridoxamine
JM Onorato et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions
PJ Thornalley et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
